Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Features include sometimes findings: Carious teeth and Increased overbite. 6 total HPO annotations.
ACP4 encodes acid phosphatase 4 (426 aa). May dephosphorylate receptor tyrosine-protein kinase ERBB4 and inhibits its ligand-induced proteolytic cleavage. May play a role in odontogenesis Highest expression in Testis (10.8 TPM) and Skin Not Sun Exposed Suprapubic (1.0 TPM).
Amelogenesis imperfecta, type 1J is associated with mutations in the ACP4 gene on chromosome 19.
ACP4 is classified as a druggable target (Enzyme and Kinase categories) with score 0.0.
12 pathogenic variants reported in ACP4 in ClinVar.
Genetic testing for ACP4 is available. Testing is considered confirmatory for diagnosis.
No clinical trials have been registered for amelogenesis imperfecta, type 1J.
1 publication has been identified in PubMed for amelogenesis imperfecta, type 1J. Research spans Basic Science / Preclinical (100%).
Hytönen MK (2025). [PMID: 39804930](https://pubmed.ncbi.nlm.nih.gov/39804930/). *PLoS Genet*. [Basic Science / Preclinical]
Data assembled from 6 of 12 sources · Last updated Sep 19, 2026, 5:35 AM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center